产品
编 号：F565782
分子式：C34H24N6Na4O16S4
分子量：992.8
分子式：C34H24N6Na4O16S4
分子量：992.8
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
400
In-stock
结构图
CAS No: 2610-05-1
产品详情
生物活性：
Direct Blue 1 (Chicago Sky Blue 6B) is a complex dye for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1 is a potent and competitive VGLUT inhibitor. Direct Blue 1 can inhibit the Aβ-binding small molecule PrP ligand. Direct Blue 1 has anti-inflammatory activity.
体内研究：
Direct Blue 1 (2 或 8 mg/kg, 皮下注射, 连续 4 周) 在小鼠中减轻了钛颗粒引起的炎症性骨破坏和骨质疏松。Direct Blue 1 (7.5 μg, 脑室注射) 可减轻甲基苯丙胺诱导的小鼠多动症和行为致敏。Animal Model:OVX-induced osteoporosis mice model
Dosage:2, 8 m/kg
Administration:s.c.
Result:Inhibited the elevated osteoclast formation and bone resorption.
Animal Model:METH-induced hyperactivity in mice
Dosage:7.5 μg
Administration:i.c.v.
Result:Reduced acute hyperactivity and attenuated expression of sensitization.
体外研究：
Direct Blue 1 (0.1, 1, 10 μM, 9 天) 可结合 α-synuclein 并抑制其聚集，从而阻断 α-synuclein在 SH-SY5Y 细胞间的增殖。Direct Blue 1 (5, 10, 20 μM, 48 h) 通过抑制 NF-κB 信号激活和促进蛋白酶体介导的 MIF 降解，在体外抑制 RANKL 诱导的破骨细胞和骨吸收。
Direct Blue 1 (Chicago Sky Blue 6B) is a complex dye for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1 is a potent and competitive VGLUT inhibitor. Direct Blue 1 can inhibit the Aβ-binding small molecule PrP ligand. Direct Blue 1 has anti-inflammatory activity.
体内研究：
Direct Blue 1 (2 或 8 mg/kg, 皮下注射, 连续 4 周) 在小鼠中减轻了钛颗粒引起的炎症性骨破坏和骨质疏松。Direct Blue 1 (7.5 μg, 脑室注射) 可减轻甲基苯丙胺诱导的小鼠多动症和行为致敏。Animal Model:OVX-induced osteoporosis mice model
Dosage:2, 8 m/kg
Administration:s.c.
Result:Inhibited the elevated osteoclast formation and bone resorption.
Animal Model:METH-induced hyperactivity in mice
Dosage:7.5 μg
Administration:i.c.v.
Result:Reduced acute hyperactivity and attenuated expression of sensitization.
体外研究：
Direct Blue 1 (0.1, 1, 10 μM, 9 天) 可结合 α-synuclein 并抑制其聚集，从而阻断 α-synuclein在 SH-SY5Y 细胞间的增殖。Direct Blue 1 (5, 10, 20 μM, 48 h) 通过抑制 NF-κB 信号激活和促进蛋白酶体介导的 MIF 降解，在体外抑制 RANKL 诱导的破骨细胞和骨吸收。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备